• The Journal of the Society of Stroke on Korean Medicine
• /
• v.17 no.1
• /
• pp.55-66
• /
• 2016

Dyslipidemia is a major risk factor for cardiovascular accidents (CVA) and heart disease, especially the ischemic type. Lowering of serum low-density lipoprotein cholesterol (LDL-C) levels is a primary measure for preventing atherosclerosis. Many medications are available for the treatment of dyslipidemia; however, these drugs have some side effects. Therefore, we treated dyslipidemia patients with Chunghyul-plus. Before treatment, patients' levels of total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and LDL-C were measured on an empty stomach. Thereafter, patients were administered 1000 mg (2 capsules) of Chunghyul-plus two or three times a day for 2 weeks. After treatment with Chunghyul-plus, patients' serum triglyceride, LDL-C, and total cholesterol levels decreased. The results of this study suggest that Chunghyul-plus might be useful in the treatment of dyslipidemia.

• Journal of Physiology & Pathology in Korean Medicine
• /
• v.30 no.3
• /
• pp.164-176
• /
• 2016

This study was perfomed to investigate the effects of Chunghyul-plus(CHP) on oxidative damage and hyperlipidemia in db/db mouse. After treatment with CHP, safety in cytotoxicity, heavy metal toxicity, production of reactive oxygen species(ROS), nitric oxide (N0) and proinflammatory cytokine IL-Ib, TNF-a, IL-6 in RAW 264.7 cells. Serum total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, insulin, GLP-1, glucose, food intake, body weight, organ weight, AST, ALT, ALP, BUN, creatine and histologic change of liver and aorta were measured in db/db mouse after oral administration of CHP. CHP showed safety in cytotoxicity and toxicity of liver and kidney for logn time administration. CHP increased the DPPH and ABTS radical scavenging activity. CHP showed significant inhibitory effect on reactive oxygen species (ROS), and showed inhibitory effect on nitiric oxide(NO) compared to control group. CHP decreased cytokine IL-6 production significantly, and decreased IL-1β and TNF-α compared to control group. CHP decreased body and organ weitht, intake food, and glucose levels compared to control group. CHP decreased total cholesterol and triglyceride significantly, and decreased LDL-cholesterol levels and increased HDL-cholesterol levels compared to control group. CHP decreased atherogenic index and cardiac risk factor significantly. CHP increased serum insulin and GLP-1 compared to control group. In histologic examination, lipophagy in the liver and aorta decreased in CHP treated mice and the cell was regular and boundary of vessel wall was clear compared to control group. These results suggest that CHP is effective in antioxidation activity and treatment and prevention of hyperlipidemia, atherosclerosis, diabetes, ischemic heart disease, stroke and other cardiocerebrovascular disease.